Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Camurus AB (publ)

Camurus is an international pharmaceutical company focused on developing treatments for severe and chronic diseases.

msh id	COM:CAMURUS
symbol	CAMX
name	Camurus AB (publ)
homepage url	https://www.camurus.com
country	SE
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	218
crunchbase url	-
linkedin url	-
founders	-

market cap	3.54B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.34
growth cost of revenue	0.32
growth depreciation and amortization	0.61
growth ebitda	5.78
growth ebitda ratio	2.77
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-1
growth gross profit	0.85
growth gross profit ratio	0.03

COM:CAMURUS

Camurus

Last Close

550.00

21/11 16:29

Market Cap

37.74B

Beta: -

Volume Today

45.51K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	109.25M
cost of revenue	109.25M
depreciation and amortization	1.29M
ebitda	50.39M
ebitda ratio	0.32
eps	0.72
eps diluted	0.69
operating expenses	96.67M
operating income	49.1M
operating income ratio	0.31

accounts receivables	-8.16M
capital expenditure	-934.04K
cash at beginning of period	52.16M
cash at end of period	109.74M
inventory	9.31M
working capital ttm	1.25B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-